Optuzumab Monatox (EPCAM/CD326) - Research Grid Biosimilar
Gecertificeerd

Optuzumab Monatox (EPCAM/CD326) - Research Grid Biosimilar

Catalog #: 10-259
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin and a truncated portion of Pseudomonas exotoxin A.

Immunogen

Humanized / EPCAM/CD326 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Cancer

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

ScFv-kappa-heavy

NCBI Organism

Homo sapiens

Other Product Names

VB4-845

Beschrijving

Optuzumab Monatox (EPCAM/CD326) - Research Grid Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamOptuzumab Monatox (EPCAM/CD326) - Research Grid Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-259